AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to manufacture them.

In 2023, however, it sold off its early-stage rare disease gene therapy portfolio to AstraZeneca's Alexion unit in a $1 billion deal, in an early sign that it was exiting the category.